GuidelineJournal of clinical gastroenterology2021
WGO Guidance for the Care of Patients With COVID-19 and Liver Disease.
Guideline in Journal of clinical gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.Hepatology international · 2024Pooled it
- Nationwide Socioeconomic Evaluation of Direct-Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023.Journal of viral hepatitis · 2026Article
- Benign course of hepatitis A and COVID-19 coinfection: A retrospective observational case series with comparative analysis.IDCases · 2026Article
- Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19.World journal of gastroenterology · 2024Article
- Insight into COVID-19 associated liver injury: Mechanisms, evaluation, and clinical implications.Hepatology forum · 2024Review
- Review
- Post-COVID-19 cholangiopathy: Systematic review.World journal of methodology · 2023Article
- Article
- A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection.Inflammopharmacology · 2023Review
- Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.World journal of gastroenterology · 2023Review
- Risk of New-Onset Liver Injuries Due to COVID-19 in Preexisting Hepatic Conditions-Review of the Literature.Medicina (Kaunas, Lithuania) · 2022Review
- Long COVID: The latest manifestations, mechanisms, and potential therapeutic interventions.MedComm · 2022Review
- Liver transplantation during COVID-19: Adaptive measures with future significance.World journal of transplantation · 2022Review
- COVID-19: Current Status in Gastrointestinal, Hepatic, and Pancreatic Diseases-A Concise Review.Tropical medicine and infectious disease · 2022Review
- Twelve Months with COVID-19: What Gastroenterologists Need to Know.Digestive diseases and sciences · 2022Review
- Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA).Digestive diseases and sciences · 2022Article
- [Key points on characteristics, diagnosis and treatment of COVID-19-associated liver injury].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- From advanced disease to transplantation: an overview of the liver at the time of COVID-19 pandemic.Internal and emergency medicine · 2022Review
- Risk Factors for Severe COVID-19 and Hepatitis C Infections: The Dual Role of Apolipoprotein E4.Frontiers in immunology · 2022Article
- Liver and COVID-19: From care of patients with liver diseases to liver injury.World journal of hepatology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 13 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the least deadly but most infectious coronavirus strain transmitted from wild animals. It may affect many organ systems. Aim of the current guideline is to delineate the effects of SARS-CoV-2 on the liver. Asymptomatic aminotransferase elevations are common in coronavirus disease 2019 (COVID-19) disease. Its pathogenesis may be multifactorial. It may involve primary liver injury and indirect effects such as "bystander hepatitis," myositis, toxic liver injury, hypoxia, and preexisting liver disease. Higher aminotransferase elevations, lower albumin, and platelets have been reported in severe compared with mild COVID-19. Despite the dominance of respiratory disease, acute on chronic liver disease/acute hepatic decompensation have been reported in patients with COVID-19 and preexisting liver disease, in particular cirrhosis. Metabolic dysfunction-associated fatty liver disease (MAFLD) has a higher risk of respiratory disease progression than those without MAFLD. Alcohol-associated liver disease may be severely affected by COVID-19-such patients frequently have comorbidities including metabolic syndrome and smoking-induced chronic lung disease. World Gastroenterology Organization (WGO) recommends that interventional procedures such as endoscopy and endoscopic retrograde cholangiopancreatography should be performed in emergency cases or when they are considered strictly necessary such as high risk varices or cholangitis. Hepatocellular cancer surveillance may be postponed by 2 to 3 months. A short delay in treatment initiation and non-surgical approaches should be considered. Liver transplantation should be restricted to patients with high MELD scores, acute liver failure and hepatocellular cancer within Milan criteria. Donors and recipients should be tested for SARS-CoV-2 and if found positive donors should be excluded and liver transplantation postponed until recovery from infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.